WO2022087694A1 - Diagnóstico de alzheimer vía saliva utilizando o método lateral flow assay - Google Patents
Diagnóstico de alzheimer vía saliva utilizando o método lateral flow assay Download PDFInfo
- Publication number
- WO2022087694A1 WO2022087694A1 PCT/BR2020/050460 BR2020050460W WO2022087694A1 WO 2022087694 A1 WO2022087694 A1 WO 2022087694A1 BR 2020050460 W BR2020050460 W BR 2020050460W WO 2022087694 A1 WO2022087694 A1 WO 2022087694A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- saliva
- diagnosis
- assay method
- lateral flow
- flow assay
- Prior art date
Links
- 210000003296 saliva Anatomy 0.000 title claims abstract description 5
- 238000003556 assay Methods 0.000 title claims abstract description 4
- 238000003745 diagnosis Methods 0.000 title claims abstract description 4
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 abstract description 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
Definitions
- Alzheimer's diagnosis via saliva using the lateral flow assay method Alzheimer's diagnosis via saliva using the lateral flow assay method.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Diagnóstico de Alzheimer via saliva utilizando o método lateral flow assay onde descobrimos os níveis da proteína beta amyloid para poder determinar se sim ou não,se o indivíduo tern a doença Alzheimer mesmo antes de apresentar sintomas mais graves.
Description
Diagnóstico de Alzheimer via saliva utilizando o método lateral flow assay.
Usamos a saliva do indivíduo a que queremos fazer o teste para então ela reagir com o Anti-p-Amyloid (anticorpo onde se localiza na “Zona de Teste” da imagem 1) onde irá apresentar cores por conta do colloidal gold(nanopartículas de ouro localizada no Suporte do conjugado da imagem 1).
Com os resultados e com as reações do processo completo do LFA, podemos descobrir as quantidades de picogramas da proteína beta amyloid e diagnosticar a doença antes de apresentar sintomas mais graves ou/até determinar estágios (pela análise de cores, podemos ver isso na imagem 4)
Imagem do produto, ao final de todas etapas de criação, pronto para uso:
FOLHAS DE SUBSTITUIÇÃO (REGRA 26)
Claims
2
1- Diagnóstico de Alzheimer caracterizado por ter o método de lateral flow assay.
2- Conforme 1 , caracterizado por utilizar saliva dos indivíduos que utilizam esse produto.
3- Conforme 1 e 2, caracterizado por utilizar o Anti-p-Amyloid.
4- Conforme 1 a 3, caracterizado por ter capa de plástico no produto.
FOLHAS DE SUBSTITUIÇÃO (REGRA 26)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR102020021929 | 2020-10-26 | ||
| BRBR102020021929-4 | 2020-10-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2022087694A1 true WO2022087694A1 (pt) | 2022-05-05 |
Family
ID=81381419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/BR2020/050460 WO2022087694A1 (pt) | 2020-10-26 | 2020-11-07 | Diagnóstico de alzheimer vía saliva utilizando o método lateral flow assay |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2022087694A1 (pt) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003062824A1 (en) * | 2002-01-23 | 2003-07-31 | Boditech Inc. | Lateral flow quantitative assay method and strip and laser-induced fluoerescence detection device therefor |
| US20090211345A1 (en) * | 2004-01-05 | 2009-08-27 | Bio-Med Photonics Co., Ltd. And Biditechmed Inc. | Method for the detection of lateral flow assay and strip and laser-induced epifluorescence and compact scanner therefor |
| WO2013153461A2 (en) * | 2012-04-13 | 2013-10-17 | Oasis Diagnostics Corporation | Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases |
| US20190284631A1 (en) * | 2016-02-29 | 2019-09-19 | eNano Health Limited | Personalized Healthcare P4 Alzheimer's Detection System and Method |
| US20200171084A1 (en) * | 2014-02-28 | 2020-06-04 | Exosome Sciences, Inc. | Brain specific exosome based diagnostics and extracorporeal therapies |
| US20200217841A1 (en) * | 2017-06-08 | 2020-07-09 | Salion Gmbh | In vitro method for the determination of neurodegenerative diseases |
-
2020
- 2020-11-07 WO PCT/BR2020/050460 patent/WO2022087694A1/pt active Application Filing
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003062824A1 (en) * | 2002-01-23 | 2003-07-31 | Boditech Inc. | Lateral flow quantitative assay method and strip and laser-induced fluoerescence detection device therefor |
| US20090211345A1 (en) * | 2004-01-05 | 2009-08-27 | Bio-Med Photonics Co., Ltd. And Biditechmed Inc. | Method for the detection of lateral flow assay and strip and laser-induced epifluorescence and compact scanner therefor |
| WO2013153461A2 (en) * | 2012-04-13 | 2013-10-17 | Oasis Diagnostics Corporation | Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases |
| US20200171084A1 (en) * | 2014-02-28 | 2020-06-04 | Exosome Sciences, Inc. | Brain specific exosome based diagnostics and extracorporeal therapies |
| US20190284631A1 (en) * | 2016-02-29 | 2019-09-19 | eNano Health Limited | Personalized Healthcare P4 Alzheimer's Detection System and Method |
| US20200217841A1 (en) * | 2017-06-08 | 2020-07-09 | Salion Gmbh | In vitro method for the determination of neurodegenerative diseases |
Non-Patent Citations (1)
| Title |
|---|
| SABBAGH MARWAN N, SHI JIONG, LEE MOONHEE, ARNOLD LISA, AL-HASAN YAZAN, HEIM JENNIFER, MCGEER PATRICK: "Salivary beta amyloid protein levels are detectable and differentiate patients with Alzheimer's disease dementia from normal controls: preliminary findings", BMC NEUROL., vol. 18, no. 1, 2018, pages 155, XP055936841, DOI: 10.1186/s12883-018-1160-y * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shi et al. | Salivary tau species are potential biomarkers of Alzheimer's disease | |
| Wang et al. | Association of low serum BDNF with depression in patients with Parkinson's disease | |
| Flaten | Aluminium as a risk factor in Alzheimer’s disease, with emphasis on drinking water | |
| Hamlet et al. | Distribution of Actinobacillus actinomycetemcomitans, Porphyromonas gingivalis and Prevotella intermedia in an Australian population | |
| EP1297187B2 (de) | Verfahren zum Nachweis von Influenza A/B-Viren in Speichel | |
| McDougall et al. | Psychometric properties of the Clinical Dementia Rating—Sum of Boxes and other cognitive and functional outcomes in a prodromal Alzheimer’s disease population | |
| Fonkoua et al. | Recent increase in meningitis caused by Neisseria meningitidis serogroups A and W135, Yaounde, Cameroon | |
| Eren et al. | Neuronal-derived EV biomarkers track cognitive decline in Alzheimer’s disease | |
| Gautam et al. | Comparative study of cerebrospinal fluid adenosine deaminase activity in patients with meningitis | |
| WO2022087694A1 (pt) | Diagnóstico de alzheimer vía saliva utilizando o método lateral flow assay | |
| DE60025605T2 (de) | Synthetische antigene zum nachweis von syphilis | |
| Ole-Nguyaine et al. | HIV-associated morbidity, mortality and diagnostic testing opportunities among inpatients at a referral hospital in northern Tanzania | |
| Chen et al. | A comparison of six clock-drawing test scoring methods in a nursing home | |
| CN114324890A (zh) | 一种检测阿尔茨海默的联检试剂盒及其应用 | |
| US6599691B1 (en) | Rapid immunoassay to detect infection with Mycobacterium tuberculosis | |
| Nair | Frequency of asymptomatic neurosyphilis in patients with latent syphilis: A 4-year retrospective study from a tertiary care center | |
| Phillips et al. | Limbic encephalitis in a child with ovarian teratoma and influenza B. Case report and critical review of the history of autoimmune anti-N-methyl-d-aspartate receptor encephalitis | |
| Jiang et al. | Evaluation of gastric lavage efficiency and utility using a rapid quantitative method in a swine paraquat poisoning model | |
| Field | Multiple sclerosis: Relation to scrapie and slow infection; ageing and measles | |
| Kumar et al. | Activity of homoeopathic drug sulphur with different potencies on lawn culture of escherichia coli and candida albicans–topically an in-vitro evaluation | |
| JP2011516883A (ja) | Ｅｒｋ１／ｅｒｋ２のリン酸化比のアルツハイマー病特異的な変化―アルツハイマー病に特異的な分子バイオマーカー（ａｄｓｍｂ） | |
| DE102020209412B4 (de) | Mittel und Verfahren zur An- oder Abreicherung und zum Nachweis von Coronaviren | |
| Alessi et al. | TPHA test. Experience at the Clinic of Dermatology, University of Milan. | |
| Reitan et al. | A short screening examination for impaired brain functions in early school-age children | |
| OKANI et al. | TYPHOID FEVER IN NIGERIA REAL OR UNREAL THE SOUTH EASTERN NIGERIA EXPERIENCE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20958924 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 20958924 Country of ref document: EP Kind code of ref document: A1 |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 20958924 Country of ref document: EP Kind code of ref document: A1 |